What is ENYO Pharma?
Headquartered in Lyon, France, ENYO Pharma is dedicated to addressing rare and common kidney diseases. The company has amassed extensive clinical data from nine completed studies involving approximately 400 subjects, demonstrating a strong foundation for its proprietary drug candidates. ENYO Pharma's mission centers on enhancing the quality of life for patients suffering from kidney ailments, with a strategic focus on preventing the need for dialysis or transplantation. The company's commitment to innovation in nephrology positions it as a key player in the biopharmaceutical landscape.
How much funding has ENYO Pharma raised?
ENYO Pharma has raised a total of $103.7M across 4 funding rounds:
Series A
$24M
Grant
$2.7M
Series B
$40M
Series C
$37M
Series A (2016): $24M with participation from Bpifrance, Sofinnova Partners, and Morningside Group
Grant (2016): $2.7M, investors not publicly disclosed
Series B (2018): $40M supported by OrbiMed
Series C (2025): $37M featuring Andera Partners, Morningside Ventures, and OrbiMed
Key Investors in ENYO Pharma
OrbiMed
OrbiMed is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health. They support companies at various stages of development, from early-stage ventures to established organizations.
Bpifrance
Bpifrance is a French public investment bank that finances companies at every stage of their development, supporting innovation, international expansion, and export activities.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm focused on life sciences, specializing in healthcare and sustainability. They act as company builders across the entire value chain of life sciences investments.
What's next for ENYO Pharma?
With the recent infusion of $37M in a major strategic investment, ENYO Pharma is poised to accelerate its development pipeline. This capital injection, contributing to the company's overall funding of $103.7M, will likely support the progression of its drug candidates through advanced clinical trials and potentially towards regulatory submission. The company's focus on rare and common kidney diseases, coupled with its established clinical data, suggests a strategic expansion into new therapeutic areas or a deepening of its existing research. Future endeavors may include strategic partnerships or further financing rounds to sustain its growth trajectory and bring its innovative treatments to patients.
See full ENYO Pharma company page
